- Trials with a EudraCT protocol (176)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
176 result(s) found for: Sodium MRI.
Displaying page 4 of 9.
EudraCT Number: 2004-003295-10 | Sponsor Protocol Number: C0524T05 | Start Date*: 2006-05-17 |
Sponsor Name:Centocor BV | ||
Full Title: A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Golimumab, a Fully Human Anti-TNFalfa Monoclonal Antibody, Administered Subcutaneously, in Methotrexate-naïve Subjects with Acti... | ||
Medical condition: Active Rheumatoid Arthritis (methotrexate [MTX]-naïve) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) AT (Completed) HU (Completed) ES (Completed) IT (Completed) | ||
Trial results: View results |
EudraCT Number: 2015-005776-24 | Sponsor Protocol Number: MRY-IIA-2015-01 | Start Date*: 2016-10-27 | |||||||||||
Sponsor Name:Dr. Manuel Rodríguez Yáñez | |||||||||||||
Full Title: Intensive treatment of blood pressure in acute ischemic stroke. TICA 2 study. | |||||||||||||
Medical condition: Acute ischemic stroke | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2005-005552-41 | Sponsor Protocol Number: ALADIN | Start Date*: 2006-02-20 | |||||||||||
Sponsor Name:IST. DI RICERCHE FARMACOLOG. M. NEGRI | |||||||||||||
Full Title: Effect of long-acting somatostatin on disease progression in nephropathy due to autosomal dominant polycystic disease a long-term three year follow-up study | |||||||||||||
Medical condition: Autosomal Dominant Polycystic Kidney Disease ADPKD | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-019025-33 | Sponsor Protocol Number: 156-09-284 | Start Date*: 2010-08-31 | |||||||||||
Sponsor Name:Otsuka Pharmaceutical Development Commercialization, Inc. | |||||||||||||
Full Title: A Phase IIa, Single-Center Study, Investigating the Short-Term Renal Hemodynamic Effects, Safety and Pharmacokinetics/Pharmacodynamics of Oral Tolvaptan (OPC-41061) in Subjects with Autosomal Domin... | |||||||||||||
Medical condition: Autosomal Dominant Polycystic Kidney Disease (ADPKD) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-001465-20 | Sponsor Protocol Number: FMLD-ARSIDOS-48 | Start Date*: 2022-02-11 | |||||||||||
Sponsor Name:Laboratorios Farmalíder S.A. | |||||||||||||
Full Title: A double-blind, multicenter, randomized clinical trial to assess the efficacy and safety of Montelukast in patients with erosive / inflammatory arthrosis of the hands | |||||||||||||
Medical condition: Erosive / inflammatory arthrosis of the hands | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Temporarily Halted) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-001579-30 | Sponsor Protocol Number: TV5600-CNS-20006 | Start Date*: 2014-11-27 | |||||||||||
Sponsor Name:Teva Pharmaceutical Industries Ltd. | |||||||||||||
Full Title: A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Once Daily Oral Administration of Laquinimod (... | |||||||||||||
Medical condition: Primary Progressive Multiple Sclerosis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) IT (Completed) ES (Completed) DE (Completed) NL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-001471-36 | Sponsor Protocol Number: PrimeRT-2018 | Start Date*: 2020-10-05 | |||||||||||
Sponsor Name:NHS Greater Glasgow and Clyde [...] | |||||||||||||
Full Title: Priming the Tumour MicroEnvironment for Effective Treatment with Immunotherapy in Locally Advanced Rectal Cancer: A Phase II trial of Durvulamab in Combination with Extended Neoadjuvant Regimens i... | |||||||||||||
Medical condition: Rectal Cancer. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-004675-31 | Sponsor Protocol Number: AMCmedonc17-010 | Start Date*: 2019-11-13 |
Sponsor Name:Academic Medical Center | ||
Full Title: A randomized Phase II study of second line treatment with liposomal irinotecan and S1 versus liposomal irinotecan and 5-fluorouracil in patients with metastatic pancreatic cancer who failed on firs... | ||
Medical condition: pancreatic cancer | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Ongoing) ES (Ongoing) IT (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2018-001516-30 | Sponsor Protocol Number: GDX-44-007 | Start Date*: Information not available in EudraCT | ||||||||||||||||
Sponsor Name:GUERBET | ||||||||||||||||||
Full Title: Pharmacokinetics, safety and efficacy of a new gadolinium-based contrast agent, gadopiclenol, in pediatric patients from 2 to 17 years of ageundergoing contrast-enhanced MRI. | ||||||||||||||||||
Medical condition: Pediatric subjects from 2 to 17 years old scheduled to undergo routine gadolinium contrast enhanced Magnetic Resonance Imaging of Central Nervous System | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |||||||||||||||||
Trial protocol: SK (Ongoing) PL (Completed) BG (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2008-003175-45 | Sponsor Protocol Number: TRIO 016 | Start Date*: 2009-01-12 | |||||||||||
Sponsor Name:Cancer International Research Group | |||||||||||||
Full Title: A randomized phase II, open-label multicenter trial of panobinostat monotherapy in women with HER2 positive locally recurrent or metastatic breast cancer | |||||||||||||
Medical condition: HER-2 positive locally recurrent or metastatic breast cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: FR (Completed) BE (Completed) GB (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-000447-27 | Sponsor Protocol Number: USKH_VL1 | Start Date*: 2012-07-25 |
Sponsor Name:Universitätsklinikum Schleswig-Holstein, Campus Kiel | ||
Full Title: Open Label Study for the Functional Characterization of Drug Metabolism and Transport in patients before routine visceral surgery | ||
Medical condition: Pharmacokinetic trial in patients, with a good general condition before standard abdominal surgery | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Temporarily Halted) | ||
Trial results: (No results available) |
EudraCT Number: 2018-002717-35 | Sponsor Protocol Number: P170920J | Start Date*: 2018-12-13 | |||||||||||
Sponsor Name:ASSISTANCE PUBLIQUE - HÔPITAUX DE PARIS (AP-HP) | |||||||||||||
Full Title: Non inferiority multicenter phase III randomized trial comparing preoperative chemotherapy only to chemoradiotherapy for locally advanced resectable rectal cancer (intergroup FRENCH-GRECCAR- PRODIGE) | |||||||||||||
Medical condition: Adults ≥ 18 years with middle or low locally advanced resectable rectal carcinoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-000420-38 | Sponsor Protocol Number: 2021-01755 | Start Date*: 2023-09-18 |
Sponsor Name:Universitätsmedizin Göttingen | ||
Full Title: Dapagliflozin in patients with Right Heart Failure (Dapa-RHF) | ||
Medical condition: Right heart failure defined as (criteria a-c must all be fulfilled): a) Reduced right ventricular systolic function or RV strain defined as at least one of the following b) N-terminal pro-BNP (NT... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2020-000698-26 | Sponsor Protocol Number: FGCL-3019-093 | Start Date*: 2023-01-17 | |||||||||||
Sponsor Name:FibroGen, Inc. | |||||||||||||
Full Title: A Phase 3, Randomized, Double-Blind, Trial of Pamrevlumab (FG-3019) or Placebo in Combination with Systemic Corticosteroids in Subjects with Non-ambulatory Duchenne Muscular Dystrophy (DMD) | |||||||||||||
Medical condition: Non-ambulatory Duchenne Muscular Dystrophy | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: FR (Prematurely Ended) AT (Prematurely Ended) CZ (Prematurely Ended) NL (Prematurely Ended) BE (Prematurely Ended) GB (GB - no longer in EU/EEA) IT (Prematurely Ended) ES (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-002249-13 | Sponsor Protocol Number: 3125001 | Start Date*: 2019-02-04 | ||||||||||||||||
Sponsor Name:Orion Corporation Orion Pharma | ||||||||||||||||||
Full Title: SAFETY AND PHARMACOKINETICS OF ODM-209 IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER OR ESTROGEN RECEPTOR-POSITIVE, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2-NEGATIVE ADVANCED BRE... | ||||||||||||||||||
Medical condition: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER OR ESTROGEN RECEPTOR-POSITIVE, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2-NEGATIVE ADVANCED BREAST CANCER | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: FI (Completed) DK (Completed) ES (Prematurely Ended) IT (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2017-003076-31 | Sponsor Protocol Number: VXM01-AVE-04-INT | Start Date*: 2018-10-10 | |||||||||||
Sponsor Name:VAXIMM GmbH | |||||||||||||
Full Title: An open-label, Phase I/II multicenter clinical trial of VXM01 in combination with avelumab in patients with progressive glioblastoma following standard treatment with or without second surgery. | |||||||||||||
Medical condition: Progressive glioblastoma (WHO grade IV) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) NL (Ongoing) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-003647-30 | Sponsor Protocol Number: LAQ-MS-305 | Start Date*: 2013-01-18 | |||||||||||
Sponsor Name:Teva Pharmaceutical Industries Ltd | |||||||||||||
Full Title: A multinational, multicenter, randomized, double-blind, parallel-group, placebo-controlled study followed by an active treatment period, to evaluate the efficacy, safety and tolerability of two dos... | |||||||||||||
Medical condition: Relapsing remitting multiple sclerosis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) GB (Prematurely Ended) LV (Prematurely Ended) DE (Prematurely Ended) HU (Prematurely Ended) ES (Prematurely Ended) GR (Prematurely Ended) EE (Prematurely Ended) CZ (Completed) IT (Prematurely Ended) AT (Prematurely Ended) PL (Prematurely Ended) BG (Prematurely Ended) SK (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-000946-41 | Sponsor Protocol Number: 63935937MYF2001 | Start Date*: 2015-06-17 | |||||||||||
Sponsor Name:Geron Corporation | |||||||||||||
Full Title: A Randomized, Single-Blind, Multicenter Phase 2 Study to Evaluate the Activity of 2 Dose Levels of Imetelstat in Subjects with Intermediate-2 or High-Risk Myelofibrosis (MF) Relapsed/Refractory to ... | |||||||||||||
Medical condition: Myelofibrosis (MF) is classified as a myeloproliferative neoplasm (MPN) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) DE (Completed) GB (Completed) ES (Completed) FR (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-004539-36 | Sponsor Protocol Number: 16NC06 | Start Date*: 2020-05-19 | ||||||||||||||||
Sponsor Name:Great Ormond Street Hospital for Children NHS Foundation Trust | ||||||||||||||||||
Full Title: Study of Montelukast In Children with Sickle Cell Disease (SMILES) | ||||||||||||||||||
Medical condition: Sleep-disordered breathing | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Children, Under 18 | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-001439-30 | Sponsor Protocol Number: ALS-Gd64/001 | Start Date*: 2013-03-22 |
Sponsor Name:Navitas Life Sciences GmbH | ||
Full Title: Exploratory evaluation of the potential for long-term retention of Gadolinium in the bones of patients who have received Gadolinium based Contrast Agents according to their medical history. | ||
Medical condition: Retention of gadolinium/traces of metals/minerals to be determined in bone/skin specimens and evaluation of signs of nephrogenic systemic fibrosis in skin. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) ES (Prematurely Ended) PL (Completed) | ||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
